文献速递生殖医学

胚胎移植前宫腔内注射hCG的个体参与者数据荟萃分析

Intrauterine human chorionic gonadotropin administration before embryo transfer (IHABT): an individual participant data meta-analysis of randomized controlled trials.
PubMed 文献 · Hum Reprod Update · 2026-01-01

该个体参与者数据荟萃分析纳入7项符合可信度标准的随机对照试验共2244名IVF参与者,发现胚胎移植前宫腔内注射hCG并未改善活产率(OR 0.99,95%CI 0.83-1.19)或临床妊娠率(OR 1.04,95%CI 0.83-1.31)。未提供个体数据的试验虽显示临床妊娠改善,但均不符合可信度标准。作者建议不应将宫腔内hCG作为IVF附加治疗。

要点

  • 胚胎移植前宫腔内注射hCG不改善IVF活产率或临床妊娠率。
  • 仅纳入符合可信度标准的7项RCT共2244名参与者进行分析。
  • 不建议将宫腔内hCG作为IVF附加治疗常规提供。

核心结论

  • 胚胎移植前宫腔内注射hCG不太可能改善IVF的临床妊娠率和活产率。
  • 未提供个体数据的RCT均不符合可信度标准,其显示的临床妊娠改善不可靠。
  • 建议临床不应将宫腔内hCG作为IVF附加治疗提供。

研究设计与样本

  • 个体参与者数据荟萃分析(IPD-MA),检索截至2026年1月,无语言限制。
  • 纳入标准为比较胚胎移植前宫腔内hCG与安慰剂或无干预的RCT。
  • 检测到28项RCT,最终纳入7项提供IPD的RCT共2244名参与者。
  • 7项IPD RCT均符合可信度标准,其中6项总体低偏倚风险。
  • 采用一阶段和二阶段随机效应IPD荟萃分析,一阶段为主要分析。

主要发现

  • 宫腔内hCG组与对照组的活产率无显著差异(7项RCT,2244人,OR 0.99,95%CI 0.83-1.19)。
  • 宫腔内hCG组与对照组的临床妊娠率无显著差异(7项RCT,2244人,OR 1.04,95%CI 0.83-1.31)。
  • 无IPD的研究与有IPD的研究在活产率上存在交互作用(OR 1.99,95%CI 0.72-5.50,交互P<0.001)。
  • 无IPD的17项RCT共3152人显示临床妊娠改善(OR 1.87,95%CI 1.48-2.35,交互P=0.005)。

关键数值与推荐

  • 活产率:OR 0.99(95%CI 0.83-1.19),基于7项RCT共2244名参与者。
  • 临床妊娠率:OR 1.04(95%CI 0.83-1.31),基于7项RCT共2244名参与者。
  • 无IPD研究活产率:OR 1.99(95%CI 0.72-5.50),交互P<0.001。
  • 无IPD研究临床妊娠率:OR 1.87(95%CI 1.48-2.35),17项RCT共3152人,交互P=0.005。
  • 推荐:不应将胚胎移植前宫腔内hCG作为IVF附加治疗提供。

临床怎么用

  • 临床不应将胚胎移植前宫腔内注射hCG作为常规IVF附加治疗。
  • 咨询患者时可告知现有最高质量证据未显示该干预改善活产或临床妊娠。
  • 对既往显示获益的研究需谨慎解读,因其不符合可信度标准。

局限性

  • 仅7项RCT提供个体参与者数据,样本量有限。
  • 未提供IPD的RCT无法纳入主要分析,但其结果不符合可信度标准。
  • 研究间存在高度异质性,具体来源未完全阐明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Intrauterine administration of hCG has been considered as a promising IVF add-on before embryo transfer to improve fertility outcomes. A Cochrane review and four more recent systematic reviews all showed improved clinical pregnancy rates and/or live birth rates following intrauterine administration of hCG, however, a high unexplained heterogeneity was also present. OBJECTIVE AND RATIONALE: To investigate the effectiveness and safety of intrauterine administration of hCG before embryo transfer in participants undergoing IVF. Individual participant data meta-analysis (IPD-MA) is recognized as the gold standard for evidence synthesis due to its ability to harmonize the data and to investigate treatment-covariate interactions. In addition, with recent experiences of guideline development and systematic review production raising increasing concerns about the trustworthiness of randomized controlled trials (RCTs) in women's health research, an IPD-MA provides a unique opportunity to summarize the best available and most trustworthy evidence on this topic. SEARCH METHODS: We searched MEDLINE, Embase, Cochrane Gynaecology and Fertility Group Specialised Register, Cochrane Central Register of Controlled Trials, PsycINFO, and clinical trial registries without language restrictions up to January 2026. Inclusion criteria included RCTs comparing intrauterine administration of hCG before embryo transfer versus placebo or no intervention in participants undergoing IVF. The IPD Integrity tool and the TRACT checklist were used to evaluate the trustworthiness of studies with and without IPD, respectively. Both one-stage and two-stage random-effect IPD meta-analyses were performed with one-stage being the primary analysis. OUTCOMES: We detected 28 RCTs, of which 7 RCTs with IPD involving 2244 participants were included. All seven RCTs with IPD met trustworthiness criteria and six RCTs had overall low risk of bias. All RCTs without IPD did not meet trustworthiness criteria. IPD-MA showed intrauterine administration of hCG before embryo transfer did not improve live birth rates (7 RCTs, 2244 participants, odds ratio [OR] 0.99, 95% CI 0.83-1.19) or clinical pregnancy rates (7 RCTs, 2244 participants, OR 1.04, 95% CI 0.83-1.31). Studies without IPD showed different results from those with IPD for live birth (1.99, 0.72-5.50, P for interaction <0.001) and clinical pregnancy (1.87 (1.48-2.35), 17 RCTs without IPD, 3152 participants, P for interaction 0.005). WIDER IMPLICATIONS: Our IPD-MA has shown that intrauterine administration of hCG before embryo transfer is unlikely to improve the chance of clinical pregnancy and live birth. In the comparison between studies with IPD and without IPD, we found that none of the RCTs without IPD met trustworthiness criteria but showed a significant improvement in clinical pregnancy. We therefore suggest that intrauterine administration of hCG should not be offered as an IVF add-on in practice. REGISTRATION NUMBER: PROSPERO (CRD42020177397).

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Zou H, Abdallah KS, Wirleitner B, et al. Intrauterine human chorionic gonadotropin administration before embryo transfer (IHABT): an individual participant data meta-analysis of randomized controlled trials. Hum Reprod Update. 2026. PMID: 41990228. doi:10.1093/humupd/dmag009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。